• Pfizer commits $1B to Arvinas for share of protein degrading breast cancer drug

    2 monthes ago - By MedCity News

    Arvinas' early clinical data for its targeted protein degradation drug for breast cancer drew partnering interest from several companies. Pfizer beat them all with a deal that pays the biotech $1 billion to share in the development and commercialization of this therapy.
    Read more ...